Real-world treatment patterns and clinical outcomes in patients with radioiodine-refractory differentiated thyroid cancer (RAI-R DTC) treated with first line lenvatinib monotherapy in the United States.
Francis P WordenOlivera Rajkovic-HooleyNeil ReynoldsGary MilliganJingchuan ZhangPublished in: Endocrine (2023)
The current study reinforces the clinical effectiveness of first line lenvatinib as standard of care in patients with RAI-R DTC in real-world clinical practice in the US.